Company Filing History:
2 out of 2 
1 out of 593 Years Active: 2016-2018
Title: Innovations of Soo Jin Park
Introduction
Soo Jin Park is a notable inventor based in Daegu, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of diseases related to regulatory T cell activity. With a total of 3 patents, his work is paving the way for innovative therapeutic solutions.
Latest Patents
One of his latest patents involves a pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to the degradation of abnormal regulatory T cell activity. This invention focuses on a polypeptide that includes a bee venom-PLA2 amino acid sequence, excluding a leader sequence, as an active ingredient. The secretory bee venom-phospholipase A2 activates regulatory T cells and suppresses the differentiation of Th1/Th7 cells. Consequently, this polypeptide can be utilized as a pharmaceutical composition for treating or preventing diseases associated with abnormal suppression of regulatory T cell activity, such as autoimmune diseases, allergic diseases, or neurodegenerative diseases.
Career Highlights
Soo Jin Park has worked with various organizations, including Inist St Co., Ltd. and the University-industry Cooperation Group of Kyung Hee University. His experience in these institutions has contributed to his expertise in pharmaceutical innovations.
Collaborations
He has collaborated with notable coworkers, including Hyun Su Bae and Hyo Jung Lee, who have supported his research endeavors.
Conclusion
Soo Jin Park's innovative work in the pharmaceutical field demonstrates his commitment to advancing treatments for complex diseases. His contributions are significant and continue to impact the medical community positively.